Even if INFβ and IFNα2 showed an opposite expression in the serum of MS patients compared to healthy controls (i.e., IFNβ increased, IFNα2 decreased), their serum levels would correlate with the number of spinal cord lesions. This evidence concerns the gene IFNB1 and myeloid sarcoma.